Control Bionics (Australia) Today
| CBL Stock | 0.07 0 1.47% |
PerformanceGood
| Odds Of DistressLow
|
Control Bionics is selling for under 0.069 as of the 24th of January 2026; that is 1.47 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.069. Control Bionics has less than a 17 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. The performance scores are derived for the period starting the 26th of October 2025 and ending today, the 24th of January 2026. Click here to learn more.
Business Domain Health Care Equipment & Services | Category Healthcare | Classification Health Care |
Control Bionics is entity of Australia. It is traded as Stock on AU exchange. The company has 411.96 M outstanding shares. More on Control Bionics
Moving against Control Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Control Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Control Bionics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Control Bionics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| MD CEO | Jeremy Steele | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | ||||
Control Bionics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Control Bionics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsControl Bionics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Control Bionics' financial leverage. It provides some insight into what part of Control Bionics' total assets is financed by creditors.
| |||||
Control Bionics (CBL) is traded on Australian Securities Exchange in Australia and employs 9 people. Control Bionics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.43 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Control Bionics's market, we take the total number of its shares issued and multiply it by Control Bionics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Control Bionics operates under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 411.96 M outstanding shares.
Control Bionics generates negative cash flow from operations
Check Control Bionics Probability Of Bankruptcy
Ownership AllocationControl Bionics holds a total of 411.96 Million outstanding shares. Control Bionics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Control Ownership Details
Control Bionics Historical Income Statement
Control Stock Against Markets
Control Stock Analysis Notes
About 53.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.02. Control Bionics had not issued any dividends in recent years. For more info on Control Bionics please contact Jeremy Steele at 61 3 9897 3576 or go to https://www.controlbionics.com.Control Bionics Quarterly Total Revenue |
|
Control Bionics Investment Alerts
| Control Bionics is way too risky over 90 days horizon | |
| Control Bionics has some characteristics of a very speculative penny stock | |
| Control Bionics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 6.14 M. Net Loss for the year was (6.11 M) with profit before overhead, payroll, taxes, and interest of 4.11 M. | |
| Control Bionics generates negative cash flow from operations | |
| About 53.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Control Bionics seeks ASX quotation for 8.4 million new shares - MSN |
Control Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.43 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Control Bionics's market, we take the total number of its shares issued and multiply it by Control Bionics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Control Profitablity
Control Bionics' profitability indicators refer to fundamental financial ratios that showcase Control Bionics' ability to generate income relative to its revenue or operating costs. If, let's say, Control Bionics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Control Bionics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Control Bionics' profitability requires more research than a typical breakdown of Control Bionics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.99) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.87) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.87. Management Efficiency
Control Bionics has return on total asset (ROA) of (0.4314) % which means that it has lost $0.4314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0374) %, meaning that it generated substantial loss on money invested by shareholders. Control Bionics' management efficiency ratios could be used to measure how well Control Bionics manages its routine affairs as well as how well it operates its assets and liabilities. Change To Liabilities is likely to gain to about 381.4 K in 2026, whereas Total Current Liabilities is likely to drop slightly above 2.2 M in 2026.Leadership effectiveness at Control Bionics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 24th of January, Control Bionics shows the Downside Deviation of 5.16, mean deviation of 5.39, and Risk Adjusted Performance of 0.1066. Control Bionics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Control Bionics Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Control Bionics Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Control Bionics price patterns.
Control Bionics Outstanding Bonds
Control Bionics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Control Bionics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Control bonds can be classified according to their maturity, which is the date when Control Bionics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Control Bionics Predictive Daily Indicators
Control Bionics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Control Bionics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1428.57 | |||
| Daily Balance Of Power | 1.0 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 0.0695 | |||
| Day Typical Price | 0.0693 | |||
| Period Momentum Indicator | 0.001 |
Control Bionics Forecast Models
Control Bionics' time-series forecasting models are one of many Control Bionics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Control Bionics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in Control Bionics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
Control Bionics Corporate Management
Elected by the shareholders, the Control Bionics' board of directors comprises two types of representatives: Control Bionics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Control. The board's role is to monitor Control Bionics' management team and ensure that shareholders' interests are well served. Control Bionics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Control Bionics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meagan Koeneman | Sales Director | Profile | |
| Robert Wong | Ex Director | Profile | |
| Dominik Kucera | Interim Officer | Profile | |
| BCom BCom | Company Sec | Profile |
Additional Tools for Control Stock Analysis
When running Control Bionics' price analysis, check to measure Control Bionics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Control Bionics is operating at the current time. Most of Control Bionics' value examination focuses on studying past and present price action to predict the probability of Control Bionics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Control Bionics' price. Additionally, you may evaluate how the addition of Control Bionics to your portfolios can decrease your overall portfolio volatility.